Key facts
- It has raised $27.9M; the latest was Later Stage VC in Nov 2025.
- Notable investors include China Capital Management, Tsing Stone Asset Management, Chengdu Technology Transfer Venture, Chengdu Bio-Town Investment, Wise Road Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Yongxin Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Yongxin Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yongxin Medical
Developer of high-end imaging equipment designed for nuclear medicine and molecular imaging. The company offers clinical molecular imaging product lines, preclinical molecular imaging product lines and nuclear security product lines, thereby providing clients with local nuclear molecular imaging equipment.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2011
- Employees
- 117
- Website
- novelmedical.cn/
- Ownership
- Privately Held (backing)
Yongxin Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yongxin Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yongxin Medical in its N-PORT filings yet. We sweep new filings monthly.